Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Clever Leaves receives Australian GMP certification

Clever Leaves has been granted Australian GMP certification for its facilities in Colombia by the Therapeutic Goods Administration (TGA), the regulatory body for health products in Australia. This certification authorizes Clever Leaves to manufacture cannabis products for patients in Australia, marking a significant achievement for the multinational operator.

Similar to the stringent standards of the EU-GMP certification, the Australian GMP certification from the TGA ensures the delivery of the highest quality medicinal cannabis to patients. It safeguards against product contamination, variations in compound concentrations, mix-ups, incorrect labeling, and other potential issues. This certification is a prerequisite for the manufacturing and commercialization of cannabis products in the Australian market.

Australia, with a population of approximately 26 million, has established a regulatory framework for the use of medical cannabis products under TGO 93 and related regulations. According to official data from the TGA, during the first half of 2023, there were 325,000 new patients reported as having commenced the treatment during this period of time. In 2022, the number of new patients was 320,000 for the full year, and in 2021, this number was 150,000.1 The official data shows that the number of patients is increasing in a sustainable way on a yearly basis.

Andres Fajardo, CEO of Clever Leaves, emphasized the significance of receiving Australian-GMP certification, stating, "The awarding of Australian-GMP certification signifies a major milestone for Clever Leaves by further highlighting our commitment to producing high-quality and safe cannabis products in one of the fastest growing and largest medicinal cannabis markets globally. We will continue distributing through our partners, with whom we are already distributing finished cannabis products to patients in the country."

For more information:
Curaleaf
info@curaleaf.com
curaleaf.com


Publication date:


FreshPublishers © 2005-2024 MMJDaily.com

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber